Sindrom Metabolik

01Pathophysiology

Metabolic syndrome is not a single disease but a clustering of interrelated cardiovascular risk factors unified by a common pathophysiological driver: insulin resistance.

The process begins with visceral (central) adiposity. Unlike subcutaneous fat, visceral adipose tissue is metabolically active and secretes pro-inflammatory cytokines such as TNF-alpha and IL-6, along with reduced levels of the protective adipokine adiponectin. This chronic inflammatory milieu impairs insulin signaling at the receptor and post-receptor levels, particularly in skeletal muscle, liver, and adipose tissue itself.

When insulin resistance develops in the liver, hepatic glucose output increases because insulin can no longer suppress gluconeogenesis effectively. This is why patients have elevated fasting glucose. Simultaneously, the liver ramps up VLDL production, which drives hypertriglyceridemia. Cholesteryl ester transfer protein (CETP) then facilitates the exchange of triglycerides from VLDL into HDL particles, making HDL triglyceride-rich and susceptible to hepatic lipase degradation. This explains the characteristic lipid pattern: high triglycerides and low HDL.

In the vasculature, insulin resistance leads to endothelial dysfunction. Normally, insulin stimulates nitric oxide (NO) production for vasodilation. In the resistant state, the NO pathway is blunted while the MAPK (mitogen-activated protein kinase) pathway remains active, promoting vasoconstriction, smooth muscle proliferation, and a pro-thrombotic state. Additionally, the sympathetic nervous system becomes overactivated, and the renin-angiotensin-aldosterone system (RAAS) is upregulated, both of which contribute to hypertension.

The pancreatic beta cells initially compensate by producing more insulin (compensatory hyperinsulinemia), which is why fasting glucose may remain normal early on. The visible clinical clue to this hyperinsulinemic state is acanthosis nigricans, caused by insulin binding to IGF-1 receptors on keratinocytes, stimulating their proliferation. When beta cell compensation eventually fails, the patient transitions from metabolic syndrome to overt type 2 diabetes mellitus.

Understanding this chain is critical because test-writers expect you to connect each diagnostic criterion back to insulin resistance rather than treating them as unrelated findings.

02Classification and Clinical Manifestation

Multiple organizations have proposed diagnostic criteria. The most commonly tested framework uses the NCEP ATP III definition (later harmonized in 2009).

NCEP ATP III

The patient does not need to have diabetes to qualify. A fasting glucose of 100 mg/dL is well below the diabetic threshold of 126 mg/dL. Students who associate metabolic syndrome only with frank diabetes will miss cases where glucose is only mildly elevated.

The waist circumference criterion reflects visceral adiposity and is not interchangeable with BMI. A patient can have a BMI of 27 (overweight but not obese) and still meet the waist circumference cutoff. Conversely, a patient with a high BMI due to muscle mass may not meet it.

Patients already on treatment for any component still count toward the criteria. A vignette describing a patient on a statin with controlled triglycerides and on lisinopril with controlled blood pressure still satisfies two criteria.

03Diagnostic Workup

Metabolic syndrome is a clinical diagnosis, not a laboratory diagnosis. There is no single confirmatory test. The "best initial test" framework does not apply in the traditional sense because you are checking a defined checklist of five criteria using basic clinical measurements and routine labs.

The workup is straightforward: measure waist circumference, obtain a fasting lipid panel, check fasting glucose, and record blood pressure. If 3 of the 5 criteria are met, the diagnosis is established.

However, once the diagnosis is made, further workup is warranted to assess end-organ damage and comorbidities. HbA1c or an oral glucose tolerance test (OGTT) should be performed to determine whether the patient has progressed to prediabetes or diabetes. Liver enzymes and hepatic ultrasound should be considered because non-alcoholic fatty liver disease (NAFLD) is present in the majority of patients with metabolic syndrome and independently increases cardiovascular risk. Uric acid is frequently elevated due to insulin-mediated reduction in renal urate excretion, and its presence supports the clinical picture.

A fasting insulin level or HOMA-IR (Homeostatic Model Assessment for Insulin Resistance, calculated as $\frac{\text{fasting insulin}\times \text{fasting glucose}}{405}\backslash frac\{\backslash text\{fasting\; insulin\}\; \backslash times\; \backslash text\{fasting\; glucose\}\}\{405\}$) can quantify insulin resistance but is not part of routine clinical criteria. It is more commonly referenced in research and in the context of polycystic ovary syndrome evaluation.

The test-writer's angle here: do not order exotic or invasive tests. The vignette will give you the five parameters, and your job is to recognize the pattern and count to three.

04Management and Treatment

Lifestyle modification is always the first-line treatment and the most commonly tested "next best step" when a vignette presents a newly diagnosed patient. The target is 7-10% reduction in body weight, which has been shown to significantly improve all five components of the syndrome. Exercise independently improves insulin sensitivity even before weight loss occurs by increasing GLUT4 transporter expression in skeletal muscle.

Dietary intervention should emphasize reduction of refined carbohydrates and saturated fats. The Mediterranean diet has the strongest evidence for reducing cardiovascular events in this population. The DASH diet is the preferred recommendation when hypertension is the dominant component.

Pharmacotherapy is directed at individual components when lifestyle modifications are insufficient. There is no single drug that treats metabolic syndrome as a whole, though GLP-1 receptor agonists (semaglutide, liraglutide) come the closest by addressing obesity, hyperglycemia, and cardiovascular risk simultaneously. These agents work by enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and promoting satiety through central appetite regulation.

Metformin is considered when fasting glucose is in the prediabetic range (100-125 mg/dL), particularly in patients under 60 with BMI $\ge \backslash geq$ 35, women with prior gestational diabetes, or those with rising HbA1c despite lifestyle changes. Its mechanism of reducing hepatic glucose output directly addresses the pathophysiology discussed earlier.

For dyslipidemia, statins are selected based on 10-year ASCVD risk calculation rather than triglyceride or LDL levels alone. The primary goal is LDL reduction and cardiovascular event prevention. Fibrates are reserved for severely elevated triglycerides (>500 mg/dL) to prevent pancreatitis, not primarily for cardiovascular risk reduction.

For the hypertension component, ACE inhibitors or ARBs are preferred because they provide cardiovascular and renal protection and have favorable metabolic profiles (they do not worsen insulin resistance). Thiazide diuretics and beta-blockers can worsen glucose tolerance and lipid profiles, so they are less ideal first-line choices in this population, though they may still be necessary for blood pressure control.

Bariatric surgery produces the most durable weight loss and can lead to complete resolution of metabolic syndrome in a significant proportion of patients. It is considered when BMI $\ge \backslash geq$ 40 kg/m${}^2^2$, or $\ge \backslash geq$ 35 kg/m${}^2^2$ with obesity-related comorbidities, after failure of conservative measures.

05Differential Diagnosis and Distractors

The most tested distractor is Cushing syndrome. Both conditions feature truncal obesity, hypertension, and glucose intolerance, but Cushing syndrome will include additional clinical features driven by cortisol excess: wide purple striae, thin skin with easy bruising, proximal myopathy, and osteoporosis. If a vignette describes central obesity and metabolic derangements but also mentions moon facies or a buffalo hump, you must pivot toward Cushing and order a 24-hour urinary free cortisol or overnight dexamethasone suppression test rather than simply diagnosing metabolic syndrome.

The distinction between metabolic syndrome and overt type 2 diabetes is also commonly tested. Remember that metabolic syndrome is a pre-morbid risk state, not a disease endpoint. A patient with fasting glucose of 110 mg/dL has metabolic syndrome criteria fulfilled but does not have diabetes.

06Traps and High-Yield Pearls

The most common way students lose points on metabolic syndrome questions is by failing to count the criteria. A vignette will list clinical and laboratory findings, and the student must actively tally which of the five criteria are met. Partial fulfillment (only 2 of 5) does not qualify, even if the patient "looks" metabolically unhealthy. Test-writers deliberately construct vignettes where a patient meets only 2 criteria alongside an unrelated finding (e.g., elevated LDL, which is not one of the five criteria) to see if you incorrectly inflate the count.

A second trap involves confusing LDL with HDL. Elevated LDL cholesterol is a major cardiovascular risk factor but is not part of the metabolic syndrome criteria. The lipid components are triglycerides and HDL only. Students who see "dyslipidemia" and assume all lipid abnormalities count will misdiagnose.

Third, students sometimes select aggressive pharmacotherapy as the next step for a newly diagnosed patient with mild abnormalities. The answer in that scenario is virtually always lifestyle modification first. Drugs target individual components only after conservative measures have failed or when values are dangerously elevated (e.g., triglycerides >500 mg/dL risking pancreatitis).

Finally, remember that metabolic syndrome is fundamentally about cardiovascular risk prediction. The core competency being tested is whether you can identify a constellation of modifiable risk factors, recognize their shared mechanism in insulin resistance, and intervene early before the patient progresses to type 2 diabetes, myocardial infarction, or stroke. The test-writer wants to see that you understand metabolic syndrome as a window of opportunity for prevention, not merely a diagnostic label.